FTA will hurt pharmaceutical sector

Published: 2007-12-18 07:00:00

Updated: 2007-12-18 07:00:00

Korea's first generic makers could lose up to 300 billion won if a U.S.-Korea free trade agreement (FTA) goes through, according to pharmaceutical business sources.

The estimated losses are based on an assumption that if the Korean government sets up a system to suspend the approval process of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK